Our findings in NSCLC and similar evidence of a key role for the IR in other cancer types suggests that residual IGF1R and unencumbered IR signalling may have contributed to the lack of benefit of figitumumab in NSCLC trials. The gene discussed is IGF1R; the disease is cancer.